Bortezomib attenuates palmitic acid-induced ER stress, inflammation and insulin resistance in myotubes via AMPK dependent mechanism
- Authors
- Kwak, Hyun Jeong; Choi, Hye-Eun; Jang, Jinsun; Park, Soo Kyung; Bae, Young-An; Cheon, Hyae Gyeong
- Issue Date
- Aug-2016
- Publisher
- ELSEVIER SCIENCE INC
- Keywords
- Bortezomib; ER stress; AMPK; Myotube; Insulin resistance
- Citation
- CELLULAR SIGNALLING, v.28, no.8, pp.788 - 797
- Journal Title
- CELLULAR SIGNALLING
- Volume
- 28
- Number
- 8
- Start Page
- 788
- End Page
- 797
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/8067
- DOI
- 10.1016/j.cellsig.2016.03.015
- ISSN
- 0898-6568
- Abstract
- Bortezomib is an anti-cancer agent that induces ER stress by inhibiting proteasomal degradation. However, the effects of bortezomib appear to be dependent on its concentration and cellular context. Since ER stress is closely related to type 2 diabetes, the authors examined the effects of bortezomib on palmitic acid (PA)-induced ER stress in C2C12 murine myotubes. At low concentrations (<20 nM), bortezomib protected myotubes from PA (750 mu M)-induced ER stress and inflammation. Either tunicamycin or thapsigargin-induced ER stress was also reduced by bortezomib. In addition, reduced glucose uptake and Akt phosphorylation induced by PA were prevented by co-treating bortezomib (10 nM) both in the presence or absence of insulin. These protective effects of bortezomib were found to be associated with reduced JNK phosphorylation. Furthermore, bortezomib-induced AMPK phosphorylation, and the protective effects of bortezomib were diminished by AMPK knockdown, suggesting that AMPK activation underlies the effects of bortezomib. The in vivo administration of bortezomib at nontoxic levels (at 50 or 200 mu g/kg, i.p.) twice weekly for 5 weeks to ob/ob mice improved insulin resistance, increased AMPK phosphorylation, reduced ER stress marker levels, and JNK inhibition in skeletal muscle. The study shows that bortezomib reduces ER stress, inflammation, and insulin resistance in vitro and in vivo, and suggests that bortezomib has novel applications for the treatment of metabolic disorders. (C) 2016 Elsevier Inc. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의예과 > 1. Journal Articles
- 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/8067)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.